← All indications
Anus Neoplasms
Tumors or cancer of the ANAL CANAL.
Subtype terms (1)
More specific conditions that are subtypes of Anus Neoplasms in the MeSH hierarchy.
Drugs by status
Phase 3 trials (17)
Phase 2 trials (34)
- fluorothymidine
- arnebia indigo jade pearl
- artemisinin
- cidofovir
- dpx-e7 vaccine
- durvalumab
- e6 tcr
- e7 tcr transduced pbl cells
- entinostat
- aldesleukin
- Verpasep
- palonosetron
- artesunate
- lenvatinib
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- carboplatin
- interleukin-12
- cyclophosphamide
- cetuximab
- tc99m-tilmanocept
- ucpvax
- vgx-3100
- vorinostat
- young tumor infiltrating lymphocytes
- fludarabine
- docetaxel
- oxaliplatin
- fludeoxyglucose f-18
- toripalimab
- bintrafusp alfa
- +4 more
Phase 1 trials (17)
- irinotecan
- ganciclovir
- leucovorin
- 4-hydroxy-2,2,6,6-tetramethyl-1-hydroxypiperidine
- human papillomavirus 16 e7 peptide
- synthetic human papillomavirus 16 e6 peptide
- isotretinoin
- interferon alpha-2b
- tislelizumab
- abi-1968
- so-c101
- tp-1454
- crte7a2-01 tcr-t cell
- rtx-321
- hryz-t101
- stimotimagene copolymerplasmid
- scg142 tcr-t cells
Other trials (2)
Organizations
Organization Involved with Phase 3 Indications (27)
- Merck
- The EMMES Corporation
- National Cancer Institute (NCI)
- University of Pittsburgh
- AIDS Malignancy Consortium
- Blokhin's Russian Cancer Research Center
- Cancer and Leukemia Group B (CALGB)
- University of London
- Harvard University
- Eastern Cooperative Oncology Group
- ECOG-ACRIN Cancer Research Group
- Hoosier Cancer Research Network
- Northwestern University
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- UNICANCER
- University of South Florida
- Mayo Clinic
- University of California, San Francisco
- European Organisation for Research and Treatment of Cancer
- University of Texas at Houston
- University of North Carolina at Chapel Hill
- University of Erlangen-Nuremberg
- Maidstone & Tunbridge Wells NHS Trust
- University of Lorraine
- CHU Besançon
Organization Involved with Phase 2 Indications (48)
- Amgen
- Roche
- Advaxis, Inc.
- AstraZeneca
- Merck Serono
- Inovio Pharmaceuticals
- Tarveda Therapeutics
- Trial Form Support S.L.
- National Institutes of Health (NIH)
- Boston University
- Brown University
- Cancer Research UK
- Federation Francophone de Cancerologie Digestive
- Grupo Espanol Multidisciplinario del Cancer Digestivo
- Gruppo Oncologico del Nord-Ovest
- Hospital de Mataró
- Hospital Infanta Sofia
- Hospital Son Llatzer
- NRG Oncology
- Rhode Island Hospital
- Universidad Autonoma de Madrid
- Australasian Gastro-Intestinal Trials Group
- Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- University of Calgary
- Royal Marsden Hospital NHS Trust
- Virginia Mason Medical Center
- Curie Institute
- Institut Gustave Roussy
- Hospital de Manises
- University of Barcelona
- +18 more
Organization Involved with Phase 1 Indications (19)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Baylor University
- Cornell University
- Lund University
- Ohio State University
- University of Nebraska
- University of Toronto
- University of Virginia
- Cardiff University
- Vanderbilt University
- Xencor
- Accord Research
- Methodist Cancer Center, Houston, Texas
- Washington University in St. Louis
- ICON
- BioMimetix Pharmaceutical, Inc.
- Inova Health System
- Antiva Biosciences
- Shattuck Labs
Organization Involved with Other Experimental Indications (1)